ATE269070T1 - Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose - Google Patents

Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose

Info

Publication number: ATE269070T1
Authority: AT; Austria
Prior art keywords: fibrosis; trichostatin; histone; collagens; decarboxylase inhibitors
Prior art date: 1996-09-04

Application number

AT97202644T

Other languages

English (en)

Inventor

Albert Emmanuel Corneil Geerts

Toshiro Niki

Original Assignee

Univ Bruxelles

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-04

Filing date

1997-08-29

Publication date

2004-07-15

1997-08-29 Application filed by Univ Bruxelles filed Critical Univ Bruxelles

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE269070T1 publication Critical patent/ATE269070T1/de

Links

206010016654 Fibrosis Diseases 0.000 title abstract 3
230000004761 fibrosis Effects 0.000 title abstract 3
108010033040 Histones Proteins 0.000 title 1
239000003954 decarboxylase inhibitor Substances 0.000 title 1
102000008186 Collagen Human genes 0.000 abstract 2
108010035532 Collagen Proteins 0.000 abstract 2
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 abstract 2
229920001436 collagen Polymers 0.000 abstract 2
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 abstract 2
102000007469 Actins Human genes 0.000 abstract 1
108010085238 Actins Proteins 0.000 abstract 1
230000000434 anti-fibrogenic effect Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
210000004024 hepatic stellate cell Anatomy 0.000 abstract 1
229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
210000004185 liver Anatomy 0.000 abstract 1
239000003550 marker Substances 0.000 abstract 1
210000000651 myofibroblast Anatomy 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
210000001626 skin fibroblast Anatomy 0.000 abstract 1
210000002460 smooth muscle Anatomy 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)

AT97202644T 1996-09-04 1997-08-29 Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose ATE269070T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP96202460A EP0827742A1 (de)	1996-09-04	1996-09-04	Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose

Publications (1)

Publication Number	Publication Date
ATE269070T1 true ATE269070T1 (de)	2004-07-15

Family

ID=8224350

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97202644T ATE269070T1 (de)	1996-09-04	1997-08-29	Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose

Country Status (8)

Country	Link
US (1)	US5993845A (de)
EP (2)	EP0827742A1 (de)
JP (1)	JPH10114681A (de)
AT (1)	ATE269070T1 (de)
DE (1)	DE69729517D1 (de)
DK (1)	DK0827743T3 (de)
ES (1)	ES2218638T3 (de)
PT (1)	PT827743E (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6822267B1 (en) *	1997-08-20	2004-11-23	Advantest Corporation	Signal transmission circuit, CMOS semiconductor device, and circuit board
CA2346152A1 (en) *	1998-10-16	2000-04-27	Novartis Ag	Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
CN1170849C (zh) *	1998-12-14	2004-10-13	迈阿密大学	结缔组织生长因子片段及其方法和用途
US6518012B1 (en)	1999-04-02	2003-02-11	Health Research, Inc.	Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
US6449625B1 (en) *	1999-04-20	2002-09-10	Lucent Technologies Inc.	Use of a two-way stack approach to optimize flash memory management for embedded database systems
PT1173201E (pt) *	1999-04-22	2005-08-31	Biogen Idec Inc	Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
EP1177796B1 (de)	1999-04-27	2011-04-27	Mitsubishi Tanabe Pharma Corporation	Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
EP1748046A3 (de) *	1999-11-23	2007-08-22	Methylgene, Inc.	Histon-Deacetylase Inhibitoren
US6544957B2 (en)	2000-01-04	2003-04-08	The Johns Hopkins University	Methods and reagents for facilitating transcription
US7078045B2 (en) *	2000-03-02	2006-07-18	Sang-Geon Kim	Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
EP1292309A4 (de) *	2000-04-07	2004-08-11	Sang Geon Kim	Prophylaktische und therapeutische verwendung von oltipraz als mittel gegen fibrose und zirrhose der leber und pharmazeutische zusammenstellung die oltipraz enthält
KR20030067935A (ko) *	2002-02-09	2003-08-19	김상건	올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
US6458589B1 (en)	2000-04-27	2002-10-01	Geron Corporation	Hepatocyte lineage cells derived from pluripotent stem cells
US7473555B2 (en)	2000-04-27	2009-01-06	Geron Corporation	Protocols for making hepatocytes from embryonic stem cells
US7256042B2 (en)	2000-04-27	2007-08-14	Geron Corporation	Process for making hepatocytes from pluripotent stem cells
US7282366B2 (en)	2000-04-27	2007-10-16	Geron Corporation	Hepatocytes for therapy and drug screening made from embryonic stem cells
GB0023983D0 (en)	2000-09-29	2000-11-15	Prolifix Ltd	Therapeutic compounds
EP1335898B1 (de)	2000-09-29	2005-11-23	TopoTarget UK Limited	Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
JP4975941B2 (ja)	2000-09-29	2012-07-11	トポターゲットユーケーリミテッド	（ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
AU2002243231A1 (en) *	2000-11-21	2002-07-24	Wake Forest University	Method of treating autoimmune diseases
DE60113645T2 (de) *	2001-04-10	2006-07-06	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
WO2002098405A1 (fr) *	2001-06-05	2002-12-12	Ajinomoto Co., Inc.	Inhibiteurs de fibrose du foie
US7229963B2 (en)	2001-10-18	2007-06-12	United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health	Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
US20030175254A1 (en) *	2001-12-21	2003-09-18	George Sachs	Method of obtaining purified enterochromaffin cells and methods of using same
AU2005227400B2 (en) *	2002-02-15	2008-04-03	Sloan-Kettering Institute For Cancer Research	Method of Treating TRX Mediated Diseases
JP2005525345A (ja) *	2002-02-15	2005-08-25	スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ	Ｔｒｘ媒介性疾患を処置する方法
CN100445276C (zh)	2002-03-13	2008-12-24	詹森药业有限公司	用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
EA007099B1 (ru)	2002-03-13	2006-06-30	Янссен Фармацевтика Н. В.	Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
MXPA04008797A (es)	2002-03-13	2004-11-26	Janssen Pharmaceutica Nv	Inhibidores de histona desacetilasa.
HRP20040805A2 (en)	2002-03-13	2005-04-30	Janssen Pharmaceutica N.V.	Carbonylamino derivatives as novel inhibitors histone deacetylase
CA2475766C (en)	2002-03-13	2012-06-05	Janssen Pharmaceutica N.V.	Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
NZ536116A (en)	2002-04-03	2007-01-26	Topotarget Uk Ltd	Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
US6809118B2 (en) *	2002-07-25	2004-10-26	Yih-Lin Chung	Methods for therapy of radiation cutaneous syndrome
US20060275370A1 (en) *	2002-07-25	2006-12-07	Yih-Lin Chung	Method and compositions for treatment of epithelial damage
US8883148B2 (en) *	2002-04-26	2014-11-11	Asan Laboratories Company (Cayman), Limited	Prevention of joint destruction
US8846039B2 (en) *	2002-04-26	2014-09-30	Asan Laboratories Company (Cayman), Limited	Method for ameliorating pruritus
US8946295B2 (en) *	2002-07-25	2015-02-03	Sunny Pharmtech Inc.	Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8163764B2 (en) *	2002-04-26	2012-04-24	Asan Laboratories Company (Cayman) Limited	Skincare methods
JP4804004B2 (ja) *	2002-08-20	2011-10-26	アステラス製薬株式会社	関節軟骨細胞外マトリクス分解阻害剤
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
EP1583736A1 (de)	2003-01-17	2005-10-12	TopoTarget UK Limited	Carbaminsäureverbindungen die eine ester- oder keton-gruppe enthalten als hdac inhibitoren
JP4790594B2 (ja)	2003-02-25	2011-10-12	トポターゲットユーケーリミテッド	Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
US7381825B2 (en)	2003-03-17	2008-06-03	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US20050058611A1 (en) *	2003-08-22	2005-03-17	L'oreal	Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
WO2005059167A1 (en) *	2003-12-18	2005-06-30	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Method for identifying histone deacetylase inhibitors
US20050197336A1 (en) *	2004-03-08	2005-09-08	Miikana Therapeutics Corporation	Inhibitors of histone deacetylase
EP1574213B1 (de) *	2004-03-11	2008-07-09	Asan Laboratories Company (Cayman), Limited	Verwendung von Histone Deacetylase Hemmern zur Steigerung der therapeutischen Wirkung in der Radiotherapie und Chemotherapie
KR20070012380A (ko) *	2004-03-26	2007-01-25	디에스엠 아이피 어셋츠 비.브이.	Ｈｄａｃ 저해제를 레티노이드와 함께 포함하는 조성물
US7345043B2 (en)	2004-04-01	2008-03-18	Miikana Therapeutics	Inhibitors of histone deacetylase
RS51189B (sr)	2004-07-28	2010-10-31	Janssen Pharmaceutica N.V.	Supstituisani derivati propenil piperazina kao novi inhibitori histonske deacetilaze
KR101261305B1 (ko)	2004-07-28	2013-05-08	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
EP1824831A2 (de)	2004-12-16	2007-08-29	Takeda San Diego, Inc.	Histondeacetylase-inhibitoren
MX2007008781A (es)	2005-01-21	2007-09-11	Astex Therapeutics Ltd	Compuestos farmaceuticos.
JP5156392B2 (ja)	2005-02-03	2013-03-06	トポターゲットユーケーリミテッド	Ｈｄａｃ阻害剤を用いる併用療法
US7772245B2 (en)	2005-02-14	2010-08-10	Miikana Therapeutics, Inc.	Inhibitors of histone deacetylase
US20100087328A1 (en) *	2005-03-01	2010-04-08	The Regents Of The University Of Michigan	Brm expression and related diagnostics
WO2006094068A2 (en) *	2005-03-01	2006-09-08	The Regents Of The University Of Michigan	Hdac inhibitors that promote brm expression and brm related diagnostics
EP1896436A2 (de)	2005-05-11	2008-03-12	Takeda San Diego, Inc.	Inhibitoren der histondeacetylase
ATE542527T1 (de)	2005-05-13	2012-02-15	Topotarget Uk Ltd	Pharmazeutische formulierungen von hdac-hemmern
ES2553178T3 (es)	2005-05-18	2015-12-04	Janssen Pharmaceutica N.V.	Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa
EA200800321A1 (ru)	2005-07-14	2008-06-30	Такеда Сан Диего, Инк.	Ингибиторы гистондеацетилазы
JP5070214B2 (ja)	2005-10-27	2012-11-07	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒストンデアセチラーゼの阻害剤としてのスクエア酸誘導体
WO2007054719A2 (en)	2005-11-10	2007-05-18	Topotarget Uk Limited	Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
DK1981871T3 (da)	2006-01-19	2012-02-13	Janssen Pharmaceutica Nv	Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase
CA2631876C (en)	2006-01-19	2014-05-27	Janssen Pharmaceutica N.V.	Aminophenyl derivatives as inhibitors of histone deacetylase
EP1981875B1 (de)	2006-01-19	2014-04-16	Janssen Pharmaceutica N.V.	Substituierte indolyl-amino-alkyl-derivate als histon-deacetylase-inhibitoren
WO2007082874A1 (en)	2006-01-19	2007-07-26	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7888360B2 (en)	2006-01-19	2011-02-15	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007082876A1 (en)	2006-01-19	2007-07-26	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8148151B2 (en)	2006-06-02	2012-04-03	Geron Corporation	Differentiation of primate pluripotent cells to hepatocyte-lineage cells
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
EP2073807A1 (de)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmazeutische kombinationen
US8642809B2 (en)	2007-09-25	2014-02-04	Topotarget Uk Ltd.	Methods of synthesis of certain hydroxamic acid compounds
WO2009118370A1 (en)	2008-03-27	2009-10-01	Janssen Pharmaceutica Nv	Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
MD4458C1 (ro) *	2014-06-19	2017-08-31	Мария ДАНУ	Utilizarea preparatului Polibiolină în tratamentul bolnavilor cu ciroză hepatică
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5674898A (en) *	1990-03-05	1997-10-07	Genzyme Corporation	Methods and therapeutic compositions for treating cystic fibrosis

1996
- 1996-09-04 EP EP96202460A patent/EP0827742A1/de not_active Withdrawn
1997
- 1997-08-29 EP EP97202644A patent/EP0827743B1/de not_active Expired - Lifetime
- 1997-08-29 PT PT97202644T patent/PT827743E/pt unknown
- 1997-08-29 AT AT97202644T patent/ATE269070T1/de not_active IP Right Cessation
- 1997-08-29 DK DK97202644T patent/DK0827743T3/da active
- 1997-08-29 DE DE69729517T patent/DE69729517D1/de not_active Expired - Lifetime
- 1997-08-29 ES ES97202644T patent/ES2218638T3/es not_active Expired - Lifetime
- 1997-09-03 US US08/922,338 patent/US5993845A/en not_active Expired - Fee Related
- 1997-09-04 JP JP9239547A patent/JPH10114681A/ja active Pending

Also Published As

Publication number	Publication date
EP0827743A1 (de)	1998-03-11
ES2218638T3 (es)	2004-11-16
DE69729517D1 (de)	2004-07-22
US5993845A (en)	1999-11-30
EP0827743B1 (de)	2004-06-16
EP0827742A1 (de)	1998-03-11
PT827743E (pt)	2004-08-31
DK0827743T3 (da)	2004-10-11
JPH10114681A (ja)	1998-05-06

Legal Events

Date	Code	Title	Description
2004-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69729517D1 (de)	2004-07-22	Verwendung von Histondecarboxylase-Hemmern zur Behandlung der Fibrose
DE69733132D1 (de)	2005-06-02	Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69831566D1 (de)	2006-01-26	Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DE69523745D1 (de)	2001-12-13	Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
KR980000447A (ko)	1998-03-30	미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
BR0116832A (pt)	2004-02-03	Produto desodorante, método cosmético e método de fabricação de composição desodorante
DE69033020D1 (de)	1999-04-29	Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
DE69805202D1 (de)	2002-06-06	Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
EA199800690A1 (ru)	1999-02-25	Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот
TW262461B (de)	1995-11-11
ATE215366T1 (de)	2002-04-15	3-benzoylphenylessigsäure-derivate enthaltende topische zusammensetzungen zur behandlung der ophthalmischen entzündungserkrankungen
PL1611088T3 (pl)	2009-11-30	Hydroksamiany jako środki terapeutyczne
ES2177112T3 (es)	2002-12-01	Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
ATE207759T1 (de)	2001-11-15	Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels
ATE442141T1 (de)	2009-09-15	Verfahren zur behandlung von stoffwechselerkrankungen mit malonyl-coa- decarboxylase-hemmern
DE69535264D1 (de)	2006-11-23	Verfahren zur behandlung von diabetes mittels kgf
ATE336997T1 (de)	2006-09-15	Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
DE69512589D1 (de)	1999-11-11	Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
EA199900542A1 (ru)	2000-02-28	Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
ATE453402T1 (de)	2010-01-15	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
BG105163A (bg)	2002-03-29	Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания
DE69625682D1 (de)	2003-02-13	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE281831T1 (de)	2004-11-15	Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
GB2331926A (en)	1999-06-09	Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine